• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Cencora Announces Date and Time for Second Quarter Fiscal 2025 Earnings Release

    3/28/25 7:00:00 AM ET
    $COR
    Other Pharmaceuticals
    Health Care
    Get the next $COR alert in real time by email

    Cencora, Inc. (NYSE:COR) today announced that it plans to release its results for the Second Quarter of Fiscal 2025 on Wednesday, May 7, 2025, prior to the opening of trading on the New York Stock Exchange. The Company will host a conference call to discuss the results at 8:30 a.m. ET on May 7, 2025.

    Participating in the conference call will be:

    Robert P. Mauch, President & Chief Executive Officer

    James F. Cleary, Executive Vice President & Chief Financial Officer

    The live call will be webcast via the Company's website at investor.cencora.com. Users are encouraged to log on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.

    To access the call via telephone from within the United States and Canada, dial (833) 470-1428. From outside the United States and Canada, dial +1 (404) 975-4839. The access code for the call will be 962235.

    Replays of the call will be made available via telephone and webcast. A replay of the webcast will be posted on investor.cencora.com approximately one hour after the completion of the call and will remain available for one year. The telephone replay will also be available approximately one hour after the completion of the call and will remain available for 7 days. To access the telephone replay from within the United States and Canada, dial 1(866) 813-9403. From outside the United States, dial 0(204) 525-0658. The access code for the replay is 839530.

    Please check the website investor.cencora.com for updates regarding the timing of the live webcasts and for replay information.

    About Cencora

    Cencora is a leading global pharmaceutical solutions organization centered on improving the lives of people and animals around the world. Cencora partners with pharmaceutical innovators across the value chain to facilitate and optimize market access to therapies. Care providers depend on Cencora for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions. Cencora's 46,000+ worldwide team members contribute to positive health outcomes through the power of Cencora's purpose: Cencora is united in its responsibility to create healthier futures. Cencora is ranked #10 on the Fortune 500 and #18 on the Global Fortune 500 with more than $290 billion in annual revenue. Learn more at investor.cencora.com.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250328424145/en/

    Bennett S. Murphy

    Senior Vice President, Head of Investor Relations and Treasury

    [email protected]

    Get the next $COR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $COR

    DatePrice TargetRatingAnalyst
    6/3/2025$337.00Equal Weight → Overweight
    Wells Fargo
    12/4/2024$280.00Outperform
    Mizuho
    9/18/2024$275.00 → $245.00Buy → Neutral
    BofA Securities
    2/26/2024$261.00Outperform
    Leerink Partners
    1/3/2024$242.00Overweight
    Barclays
    12/14/2023$213.00Equal Weight
    Wells Fargo
    12/14/2021$162.00 → $170.00Buy → Neutral
    Citigroup
    11/26/2021$136.00 → $170.00Sector Perform
    RBC Capital
    More analyst ratings